Comparative Pharmacology
Head-to-head clinical analysis: LAMPIT versus PYRIMETHAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMPIT versus PYRIMETHAMINE.
LAMPIT vs PYRIMETHAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the enzyme G6PD (glucose-6-phosphate dehydrogenase) in Trypanosoma cruzi, leading to oxidative stress and parasite death.
Pyrimethamine inhibits dihydrofolate reductase (DHFR) in the parasite, blocking the conversion of dihydrofolate to tetrahydrofolate, thereby inhibiting nucleic acid synthesis.
Nifurtimox (Lampit) for Chagas disease: adult dose 8-10 mg/kg/day orally in 3 divided doses for 90 days. For Chagas disease in children: 15-20 mg/kg/day orally in 3 divided doses for 90 days.
For toxoplasmosis: 200 mg orally once, then 50-75 mg orally once daily for 4-6 weeks, plus sulfadiazine and folinic acid. For malaria prophylaxis: 25 mg orally once weekly.
None Documented
None Documented
Clinical Note
moderatePyrimethamine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pyrimethamine."
Clinical Note
moderatePyrimethamine + Artemether
"The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Artemether."
Clinical Note
moderatePyrimethamine + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Lumefantrine."
Clinical Note
moderateTerminal elimination half-life is approximately 20 hours. In hepatic impairment, half-life may be prolonged by up to 2-fold.
Terminal elimination half-life is approximately 96 hours (range 80-123 hours) in adults with normal renal function; prolonged in renal impairment (up to 200 hours). This long half-life supports weekly dosing regimens.
Renal excretion of unchanged drug accounts for 10% of the dose; biliary/fecal excretion accounts for approximately 90%, mainly as metabolites.
Primarily renal (approximately 30% unchanged and 20-30% as metabolites); additional biliary/fecal elimination (20-30% as metabolites). Total urinary excretion of parent drug and metabolites accounts for 60-80% of dose.
Category C
Category D/X
Antiprotozoal
Antimalarial / Antiprotozoal
Cyclophosphamide + Pyrimethamine
"The metabolism of Pyrimethamine can be decreased when combined with Cyclophosphamide."